Effects of Neuralli® MP on Self-Defined Outcomes in Adults With Autistic Traits

NCT07064538 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-08-24

No results posted yet for this study

Summary

To evaluate the efficacy of Neuralli® MP in improving participant-defined outcomes in adults with autistic traits.

Conditions

  • ASD
  • Autism
  • Autistic Disorders Spectrum

Interventions

DIETARY_SUPPLEMENT

Neuralli® MP

Neuralli® MP containing 60 billion CFU (administered as two capsules per day)

Sponsors & Collaborators

  • Bened Biomedical Co., Ltd.

    collaborator INDUSTRY
  • Mackay Memorial Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-19
Primary Completion
2026-06-30
Completion
2026-08-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07064538 on ClinicalTrials.gov